Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (415)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2107)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (105)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (846)
  3. JNCI: Journal of the National Cancer Institute (485)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (138)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4652)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The gamma secretase inhibitor AL101 combined with other drugs for dual targeting of Notch dysregulated tumors
    Meeting Abstract

    Ferrarotto, R.; Rauch, R.; Leibovich, T.; Shitrit, A.; Solomon, O.; Herz, E.; Walker, R. M.; Ho, A. L.; Kaye, J.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Safety and preliminary efficacy of vimseltinib in tenosynovial giant cell tumor (TGCT)
    Meeting Abstract

    Gelderblom, H.; Abdul Razak, A. R.; Sánchez-Gastaldo, A.; Rutkowski, P.; Wilky, B.; Wagner, A.; van de Sande, M.; Michenzie, M.; Vallee, M.; Sharma, M.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Tazemetostat in combination with a PARP Inhibitor or checkpoint inhibitor in patients (Pts) with solid tumors
    Meeting Abstract

    Rudin, C. M.; Abida, W.; Spira, A.; Chadha, R.; Yang, J.; Powers, D.; Coleman, R.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Multi-omic characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation
    Meeting Abstract

    Quintanal-Villalonga, A.; Taniguchi, H.; Zhan, Y. A.; Hasan, M. M.; Chavan, S. S.; Uddin, F.; Allaj, V.; Manoj, P.; Shah, N. S.; Chan, J. M.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Ripretinib as ≥4th-line treatment in patients with advanced gastrointestinal stromal tumor: Long-term update from the phase III INVICTUS study
    Meeting Abstract

    von Mehren, M.; Heinrich, C.; George, S.; Zalcberg, J. R.; Bauer, S.; Gelderblom, H.; Schöffski, P.; Serrano, C.; Jones, R. L.; Attia, S.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • A phase Ia/Ib, dose-escalation/expansion study of the MDM2-p53 antagonist BI 907828 in patients (pts) with advanced/metastatic sarcoma
    Meeting Abstract

    Gounder, M.; Patel, M. R.; Yamamoto, N.; Bauer, T. M.; Laurie, S.; Perez-Pitarch, A.; Geng, J.; Cheng, J.; Lahmar, M.; Lorusso, P.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Adverse event management during treatment with bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1: Treatment guidelines based on experience in clinical trials
    Meeting Abstract

    Gulley, J.; Lacouture, M. E.; Spira, A.; Verdaguer Mata, H.; Yoo, C.; Cho, B. C.; Helwig, C.; Halady, T.; Valencia, C.; Bajars, M.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • POLO: Long-term safety and tolerability of olaparib for patients with a germline BRCA mutation and metastatic pancreatic cancer
    Meeting Abstract

    Arnold, D.; Golan, T.; Hammel, P.; Reni, M.; Van Cutsem, E.; Macarulla Mercade, T.; Hall, M. J.; Park, J. O.; Hochhauser, D.; Oh, D. Y.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • POLO: Subsequent therapy after maintenance olaparib in patients with a germline BRCA mutation and metastatic pancreatic cancer
    Meeting Abstract

    Golan, T.; Hammel, P.; Reni, M.; Van Cutsem, E.; Macarulla Mercade, T.; Hall, M. J.; Park, J. O.; Hochhauser, D.; Arnold, D.; Oh, D. Y.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Biomarkers of response and hyperprogression in patients with sarcoma treated with checkpoint blockade
    Meeting Abstract

    Klemen, N. D.; Hwang, S.; Bradic, M.; Rosenbaum, E.; Dickson, M.; Gounder, M.; Kelly, C. M.; Keohan, M. L.; Movva, S.; Thornton, K.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save